FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to ophthalmology, and can be used in experimental ophthalmology for simulation of retinal pigment epithelium atrophy. Bevacizumab is introduced into the subretinal space at 0.5 pd below the optic disk in amount of 10 mcl containing 0.025 mg of the preparation to form a subretinal bladder.
EFFECT: method enables to obtain a simple, adequate clinical-functional and morphological model of retinal atrophy, reflecting the course of the process closest to its occurrence with the background of anti-VEGF-therapy.
1 cl, 8 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF SIMULATING RETINAL PIGMENT EPITHELIUM ATROPHY | 2019 |
|
RU2727000C1 |
| METHOD OF SUBRETINAL TRANSPLANTATION OF RETINAL PIGMENT EPITHELIUM (RPE) CELLS DIFFERENTIATED FROM HUMAN INDUCED PLURIPOTENT STEM CELLS, WITH ATROPHY OF RETINAL PIGMENT EPITHELIUM IN EXPERIMENT | 2019 |
|
RU2729937C1 |
| METHOD OF TRANSPLANTATION OF RETINAL PIGMENT EPITHELIUM (RPE) CELLS DIFFERENTIATED FROM INDUCED HUMAN PLURIPOTENT STEM CELLS, WITH RETINAL PIGMENT EPITHELIUM ATROPHY | 2019 |
|
RU2730937C1 |
| METHOD FOR REMOVING AN ORGANIZED SUBRETINAL BLOOD CLOT IN THE MACULAR AREA | 2023 |
|
RU2792557C1 |
| METHOD FOR DETECTING AN ACTIVE DESTRUCTIVE PROCESS IN THE RETINA IN AN EXPERIMENT | 2021 |
|
RU2768588C1 |
| METHOD OF EVALUATING RETINA FUNCTIONING | 2008 |
|
RU2363370C1 |
| METHOD OF DIFFERENTIAL DIAGNOSTICS OF MYOPIC CHOROIDAL NEOVASCULARIZATION AND NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN MYOPIC EYES | 2020 |
|
RU2749120C1 |
| METHOD FOR DETERMINING STAGES OF PIGMENT AND PIGMENTLESS PIGMENT RETINITIS | 2018 |
|
RU2707368C1 |
| METHOD FOR PREDICTING THE RISK OF DEVELOPMENT OF SUBRETINAL FIBROSIS IN PATIENTS WITH EXUDATIVE FORM OF AGE-RELATED MACULAR DEGENERATION GIVEN ANTI-VEGF THERAPY | 2022 |
|
RU2793419C1 |
| METHOD OF INCREASING EFFECIENCY OF PHOTODYNAMIC THERAPY OF CHOROIDAL NEOVASCULARISATION | 2008 |
|
RU2375023C1 |
